The METAB-BELGROW-LAGH study aims to prospectively evaluate the metabolic outcomes of Belgian children diagnosed with growth hormone deficiency (GHD) over a three-year period following the initiation of treatment with either daily recombinant human growth hormone (rhGH) or weekly long-acting growth hormone (LAGH). Patients will be stratified according to their IGF-1 levels. The primary objective is to assess the metabolic outcomes of children treated with daily rhGH over the first three years. The secondary objectives include comparing the metabolic outcomes between patients treated with daily rhGH and those treated with weekly LAGH, and characterizing metabolic profiles based on IGF-1 levels. To achieve these objectives, both standard-of-care (SOC) and additional data will be collected at scheduled follow-up visits (baseline, 6, 12, 24, and 36 months), including clinical, auxological, and biological parameters. Additional metabolic markers, inflammatory and endothelial biomarkers will be assessed. In a subset of patients, carotid intima-media thickness (cIMT) and body fat distribution (via DEXA-scan) will also be measured.
Age range
5 Years – 18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Auxological evaluation_1
Timeframe: 3 years
Auxological evaluation_2
Timeframe: 3 years
Auxological evaluation_3
Timeframe: 3 years
Evaluation of the blood pressure
Timeframe: 3 years
Evaluation of waist circumference
Timeframe: 3 years
Evaluation of clinical signs of puberty (Tanner stage) and androgenism
Timeframe: 3 years
Metabolic evaluation_1
Timeframe: 3 years
Metabolic evaluation_2
Timeframe: 3 years
Metabolic evaluation_3
Timeframe: 3 years
Metabolic evaluation_4
Timeframe: 3 years
Metabolic evaluation_5
Timeframe: 3 years
Metabolic evaluation_6
Timeframe: 3 years
Metabolic evaluation_7
Timeframe: 3 years
Metabolic evaluation_8
Timeframe: 3 years
Metabolic evaluation_9
Timeframe: 3 years
Metabolic evaluation_10
Timeframe: 3 years
Bone markers_1
Timeframe: 3 years
Bone markers_2
Timeframe: 3 years
Bone markers_3
Timeframe: 3 years
Endothelial stress and inflammatory markers_1
Timeframe: 3 years
Endothelial stress and inflammatory markers_2
Timeframe: 3 years
Endothelial stress and inflammatory markers_3
Timeframe: 3 years
Endothelial stress and inflammatory markers_4
Timeframe: 3 years
Radiological evaluation of cIMT
Timeframe: 3 years
Radiological evaluation of body fat distribution
Timeframe: 3 years